247 related articles for article (PubMed ID: 27126827)
1. Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems.
Habibi M; Kuttab HM
Am J Health Syst Pharm; 2016 Jun; 73(11):811-9. PubMed ID: 27126827
[TBL] [Abstract][Full Text] [Related]
2. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
[TBL] [Abstract][Full Text] [Related]
3. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Thomas RH; Wakefield RA
Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
[TBL] [Abstract][Full Text] [Related]
4. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
[TBL] [Abstract][Full Text] [Related]
5. Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study.
Kingwell E; Zhang T; Zhu F; Walld R; Carruthers R; Evans C; Marrie RA; Tremlett H
Expert Opin Drug Saf; 2021 Apr; 20(4):481-487. PubMed ID: 33342303
[TBL] [Abstract][Full Text] [Related]
6. The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study.
Jivraj F; Kang S; Reedie S; Kapadia S; Strzok S; Elliott E; Cano S; Rock M
Adv Ther; 2022 Nov; 39(11):5072-5086. PubMed ID: 36053450
[TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
8. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Guarnera C; Bramanti P; Mazzon E
Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
[TBL] [Abstract][Full Text] [Related]
9. Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.
Eckstein C; Bhatti MT
Surv Ophthalmol; 2016; 61(3):318-32. PubMed ID: 26703886
[TBL] [Abstract][Full Text] [Related]
10. [Oral disease-modifying agents in relapsing-remitting multiple sclerosis].
Iljicsov A; Pál Z; Simó M
Neuropsychopharmacol Hung; 2015 Dec; 17(4):197-205. PubMed ID: 26727724
[TBL] [Abstract][Full Text] [Related]
11. Integrated clinical and specialty pharmacy practice model for management of patients with multiple sclerosis.
Hanson RL; Habibi M; Khamo N; Abdou S; Stubbings J
Am J Health Syst Pharm; 2014 Mar; 71(6):463-9. PubMed ID: 24589537
[TBL] [Abstract][Full Text] [Related]
12. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
13. Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs.
Pappolla A; Auger C; Sao-Aviles A; Tur C; Rodriguez-Barranco M; Cobo-Calvo Á; Mongay-Ochoa N; Rodríguez-Acevedo B; Zabalza A; Midaglia L; Carbonell-Mirabent P; Carvajal R; Castilló-Justribó J; Braga N; Bollo L; Vidal-Jordana A; Arrambide G; Nos C; Salerno A; Galán I; Comabella M; Sastre-Garriga J; Tintoré M; Rovira A; Montalban X; Río J
Mult Scler; 2024 Jun; 30(7):820-832. PubMed ID: 38551315
[TBL] [Abstract][Full Text] [Related]
14. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
15. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
Kretzschmar B; Pellkofer H; Weber MS
Curr Neurol Neurosci Rep; 2016 Apr; 16(4):38. PubMed ID: 26944956
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.
Alsaqa'aby MF; Vaidya V; Khreis N; Khairallah TA; Al-Jedai AH
Ann Saudi Med; 2017; 37(6):433-443. PubMed ID: 29229891
[TBL] [Abstract][Full Text] [Related]
17. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Gold R
CNS Drugs; 2011 Jan; 25(1):37-52. PubMed ID: 21128693
[TBL] [Abstract][Full Text] [Related]
18. Recognizing and overcoming potential barriers to oral medications for MS.
Moses H
J Clin Psychiatry; 2014 Oct; 75(10):e28. PubMed ID: 25373133
[TBL] [Abstract][Full Text] [Related]
19. Disease modifying therapies for relapsing multiple sclerosis.
Wingerchuk DM; Weinshenker BG
BMJ; 2016 Aug; 354():i3518. PubMed ID: 27549763
[TBL] [Abstract][Full Text] [Related]
20. [Oral treatments in multiple sclerosis].
Meca-Lallana JE; Hernández-Clares R; Carreón-Guarnizo E
Med Clin (Barc); 2014 Dec; 143 Suppl 3():23-9. PubMed ID: 25732946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
